glp-1 and sleep apnea The pleiotropic effects of glucagon-like peptide-1 receptor agonists GLP-1 therapies reduce OSA risk

Description

The clinical relevance of these findings is underscored by the safety profile of GLP-1 agonists in long-term use and their established efficacy in reducing cardiovascular events

Results from a 20-week phase 1b clinical trial showed that a once-weekly dose of 2.4 mg cagrilintide in combination with an equal dose of semaglutide, collectively termed cagrisema, achieved up to 17.1% weight reduction in the obese population

Put simply, this medicine makes it easier for patients to stick to their diets and helps their bodies more effectively metabolize what they eat

look no further than Blue Cross and communication around coming back and saying that through employers, theyll continue to cover it if you have diabetes, but they wont cover it if you have obesity because the the information, the data for diet and exercise is so strong